Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology

References

• Saito Y, Ruberu NN, Sawabe M, et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 2004;63:742–9
   PubMedGoogle Scholar
• Kraybill ML, Larson EB, Tsuang DW, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005;64:2069–73
   PubMed Web of Science ®Google Scholar
• Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002;164:203–12
   Google Scholar
• Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004;111:1219–35
   PubMed Web of Science ®Google Scholar
• Miller TP, Tinklenberg JR, Brooks 3rd JO, Yesavage JA. Cognitive decline in patients with Alzheimer disease: differences in patients with and without extrapyramidal signs. Alzheimer Dis 1991;5: 251–6
   Google Scholar
• Kraemer HC, Tinklenberg J, Yesavage JA. ‘How far’ vs ‘how fast’ in Alzheimer’s disease. The question revisited. Arch Neurol 1994;51:275–9
   PubMedGoogle Scholar
• Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer’s disease. Arch Neurol 1994;51:676–81
   PubMed Web of Science ®Google Scholar
• Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease. Neurology 1998;51:351–7
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer disease. Neurology 2004;63:975–82
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Albert M, Brandt J, et al. Motor signs predict poor outcomes in Alzheimer disease. Neurology 2005;64:1696–703
   PubMed Web of Science ®Google Scholar
• Tsuang DW, Purganan K, Steinbart E, et al. Concomitant Lewy body pathology a marker for more aggressive course in familial Alzheimer’s disease. 57th Annual Meeting of the American Academy of Neurology, Miami, FL, USA, 9–16 April 2005 [P06.074]
   Google Scholar
• Lopez OL, Wisnieski SR, Becker JT, Boller F, DeKosky ST. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 1997;54:969–75
   PubMedGoogle Scholar
• Soininen H, Laulumaa V, Helkala EL, Hartikainen P, Riekkinen PJ. Extrapyramidal signs in Alzheimer’s disease: a 3-year follow-up study. J Neural Transm 1992;4: 107–19
   Google Scholar
• Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer’s disease: prospective analyses from the Predictors Study. Neurology 1994;44:2300–7
   PubMed Web of Science ®Google Scholar
• Murman DL, Kuo SB, Powell MC, Colenda CC. The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology 2003;61:944–9
   PubMed Web of Science ®Google Scholar
• Drachman DA, O’Donnell BF, Lew RA, Swearer JM. The prognosis in Alzheimer’s disease. ‘How far’ rather than ‘how fast’ best predicts the course. Arch Neurol 1990;47:851–6
   Google Scholar
• Lopez OL, Wisniewski S, Hamilton RL, et al. Predictors of progression in patients with AD and Lewy bodies. Neurology 2000;54:1774–9
   PubMed Web of Science ®Google Scholar
• Burns A, Jacoby R, Levy R. Neurological signs in Alzheimer’s disease. Age Ageing 1991;20:45–51
   Google Scholar
• Samson WN, van Duijn CM, Hop WC, Hofman A. Clinical features and mortality in patients with early-onset Alzheimer’s disease. Eur Neurol 1996;36:103–6
   PubMed Web of Science ®Google Scholar
• Van Dijk PT, Dippel DW, Van Der Meulen JH, Habbema JD. Comorbidity and its effect on mortality in nursing home patients with dementia. J Nerv Ment Dis 1996;184:180–7
   Google Scholar
• Mitchell SL, Rockwood K. The association between parkinsonism, Alzheimer’s disease, and mortality: a comprehensive approach. J Am Geriatr Soc 2000;48:422–5
   PubMed Web of Science ®Google Scholar
• Haan MN, Jagust WJ, Galasko D, Kaye J. Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease. Arch Neurol 2002;59:588–93
   PubMed Web of Science ®Google Scholar
• Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 2005;21:1317–28
   PubMed Web of Science ®Google Scholar
• McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–24
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington (DC): American Psychiatric Association; 1994
   Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189–98
   Google Scholar
• Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neurological test for severely demented patients. Arch Neurol 1994;51:41–5
   PubMed Web of Science ®Google Scholar
• Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136–9
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease [The Alzheimer’s Disease Cooperative Study]. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):533–9
   Google Scholar
• Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P-F, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double blind, placebo-controlled international study. Lancet 2000;356;2031–6
   Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for the dementia associated with Parkinson’s disease. New Eng J Med 2004;351:29–38
   Google Scholar
• Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005;59:817–22
   PubMed Web of Science ®Google Scholar
• AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105–15
   Google Scholar
• Bullock R, Passmore P, Wilkinson D, et al. Participation in trials should be based on clinical uncertainty, not enforcement. Br Med J 2000;320:511 [letter]
   Google Scholar
• Schneider L. AD2000: donepezil in Alzheimer’s disease [commentary]. Lancet 2004;363:2100–1
   PubMed Web of Science ®Google Scholar
• Wesnes K, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183–92
   PubMed Web of Science ®Google Scholar
• Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001;13:199–205
   PubMed Web of Science ®Google Scholar
• Sanders J, Newby VJ, Richardson JP, et al. Donepezil in dementia with Lewy bodies: treatment and withdrawal. Int Psychogeriatr 2001;13\(Suppl 2):P–123
   Google Scholar
• Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998;10:229–38
   Google Scholar
• Lanctôt KL, Herrmann N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000;15:338–45
   Google Scholar
• Aarsland D, Brønnick K. Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999;14: 69–74
   PubMed Web of Science ®Google Scholar
• Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005;20:938–44
   PubMed Web of Science ®Google Scholar
• Walker Z, Allen RL, Shergill S, Mullan E, Katona CL. Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies. Int J Geriatr Psychiatry 2000; 15:267–73
   Google Scholar
• O’Brien KK, Saxby BK, Ballard CG, et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 2003;13:231–9
   Google Scholar
• Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003;60:1852–3
   Google Scholar
• Holmes C, Ballard C, Lehman D, et al. Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005;76:640–3
   PubMed Web of Science ®Google Scholar
• Darvesh S, Hopkins DA. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 2003;463:25–43
   PubMed Web of Science ®Google Scholar
• Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993;50:873–80
   PubMed Web of Science ®Google Scholar
• Royall DR. Bedside assessment of vascular dementia. In: Gauthier S, Erkinjuntti T, editors. Vascular cognitive impairment. London: Martin Dunitz Ltd; 2002. p. 307–22
   Google Scholar
• Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59: 563–72
   Google Scholar